[1] 日本胃癌研究会.胃癌取扱い规约[M]. 14版. 东京: 金原出版社,2010:7-12.
[2] 日本胃癌研究会.胃癌取扱い规约[M]. 15版. 东京: 金原出版社,2017:23.
[3] Farran B, Müller S, Montenegro RC.Gastric cancer management: Kinases as a target therapy[J]. Clin Exp Pharmacol Physiol,2017,44(6):613-622.
[4] Lazãr DC, Avram MF, Romoşan I, et al. Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer[J]. World J Gastroenterol,2018,24(32):3583-3616.
[5] 李国立, 鲍阳, 李宁, 等. 以淋巴结转移为主的晚期胃癌的FLEP法新辅助化疗[J]. 外科理论与实践,2005, 10(5):425-427.
[6] 李国立, 鲍阳, 姜军, 等. 动静脉联合给药的FLEOX新辅助化疗加营养支持提高晚期胃癌可切除率[J]. 中华胃肠外科杂志,2008,11(5):428-431.
[7] 李国立, 范朝刚, 鲍扬, 等. 动静脉结合给药的FLEEOX方案对以淋巴结转移为主晚期胃癌的新辅助化疗[J]. 中华外科杂志,2009,47(15):1171-1174.
[8] Zhang C, Li G, Fan C, et al.Comparison of efficacy of different route of administration of chemotherapy on unresectable, advanced gastric cancer[J]. World J Surg Oncol,2012,10:162.
[9] He Q, Li Y, Ma L, et al.Application of FLEEOX preo-perative chemotherapy via intra-arterial and intravenous administration in treatment of unresectable locally advanced gastric cancer[J]. J Gastrointest Surg,2016,20(8):1421-1427.
[10] 李国立, 曹建明, 刘福坤, 等. 血管造影在胃癌诊断中的应用[J]. 中华外科杂志,1997,35(8):478-480.
[11] 李国立, 刘福坤, 黎介寿. 术前判断胃癌生长方式的方法及其临床意义[J]. 医学研究生学报,2003,16(5):368-371.
[12] 李国立, 刘福坤, 黎介寿. 胃癌术前分期CT诊断与手术及病理的对比[J]. 世界华人消化杂志,1999,7(9):817-818.
[13] 李国立, 郑玲, 刘福坤, 等. 胃癌淋巴结转移的CT分组定位诊断法[J]. 外科理论与实践,2003,8(3):226-229.
[14] Yamada Y, Higuchi K, Nishikawa K, et al.Phase Ⅲ study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer[J]. Ann Oncol,2015,26(1):141-148.
[15] Liu K, Li G, Fan C, et al.Adapted Choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy[J]. Acta Radiol,2012,53(2):127-134.
